314.40

1.92% 5.92

Alnylam Pharmaceuticals Inc (ALNY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ALNY Giù? Forum Previsione

Precedente Chiudi:

$308.48

Aprire:

$302.55

Volume 24 ore:

1.39M

Relative Volume:

0.94

Capitalizzazione di mercato:

$41.54B

Reddito:

$3.21B

Utile/perdita netta:

$43.57M

Rapporto P/E:

1,307.28

EPS:

0.2405

Flusso di cassa netto:

$221.36M

1 W Prestazione:

-4.19%

1M Prestazione:

-15.02%

6M Prestazione:

-27.31%

1 anno Prestazione:

+18.69%

Intervallo 1D:

$302.55

$318.44

Intervallo di 1 settimana:

$298.00

$329.92

Portata 52W:

$205.87

$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Nome

Alnylam Pharmaceuticals Inc

Settore

Healthcare (1111)

Industria

Biotechnology (622)

Telefono

(617) 551-8200

Indirizzo

675 WEST KENDALL STREET, CAMBRIDGE, MA

Dipendente

2,230

Cinguettio

@alnylam

Prossima data di guadagno

2026-02-12

Ultimi documenti SEC

ALNY's Discussions on Twitter

Compare ALNY vs VRTX, REGN, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-28	Ripresa	Barclays	Overweight
2026-01-07	Ripresa	Oppenheimer	Outperform
2025-08-04	Aggiornamento	Oppenheimer	Perform → Outperform
2025-08-04	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2025-07-30	Ripresa	Raymond James	Outperform
2025-07-21	Iniziato	Truist	Buy
2025-03-31	Iniziato	Redburn Atlantic	Buy
2025-03-24	Aggiornamento	JP Morgan	Neutral → Overweight
2024-11-12	Downgrade	Wolfe Research	Peer Perform → Underperform
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-08-16	Aggiornamento	Goldman	Neutral → Buy
2024-02-16	Downgrade	Goldman	Buy → Neutral
2024-02-15	Iniziato	Wolfe Research	Peer Perform
2023-12-08	Iniziato	Wells Fargo	Equal Weight
2023-10-11	Downgrade	Oppenheimer	Outperform → Perform
2023-09-29	Iniziato	Raymond James	Outperform
2023-05-05	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-04-26	Iniziato	SMBC Nikko	Neutral
2023-03-21	Iniziato	Bernstein	Outperform
2023-01-18	Iniziato	Canaccord Genuity	Buy
2022-09-09	Ripresa	Morgan Stanley	Equal-Weight
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-06-27	Downgrade	Guggenheim	Buy → Neutral
2022-06-07	Iniziato	William Blair	Outperform
2022-04-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-03-01	Iniziato	Citigroup	Buy
2022-02-03	Aggiornamento	Guggenheim	Neutral → Buy
2022-01-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2021-11-22	Aggiornamento	Goldman	Neutral → Buy
2021-11-22	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2021-11-01	Aggiornamento	Oppenheimer	Perform → Outperform
2021-10-04	Aggiornamento	UBS	Neutral → Buy
2021-08-04	Downgrade	Piper Sandler	Overweight → Neutral
2021-02-22	Downgrade	Guggenheim	Buy → Neutral
2021-02-12	Downgrade	Citigroup	Buy → Neutral
2021-02-12	Reiterato	H.C. Wainwright	Buy
2021-01-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
2020-09-30	Ripresa	Berenberg	Hold
2020-09-08	Iniziato	Citigroup	Buy
2020-08-11	Downgrade	Oppenheimer	Outperform → Perform
2020-05-13	Iniziato	RBC Capital Mkts	Sector Perform
2020-05-07	Downgrade	JP Morgan	Overweight → Neutral
2020-04-24	Ripresa	Evercore ISI	Outperform
2020-03-19	Iniziato	Berenberg	Buy
2019-12-19	Reiterato	Chardan Capital Markets	Buy
2019-11-20	Iniziato	Oppenheimer	Outperform
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-05-23	Ripresa	Goldman	Neutral
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-03-06	Aggiornamento	Evercore ISI	In-line → Outperform
2019-03-05	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2019-01-23	Iniziato	UBS	Neutral
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-08-13	Reiterato	Stifel	Buy
2018-08-07	Aggiornamento	Stifel	Hold → Buy
2018-05-04	Reiterato	Stifel	Hold
2018-03-28	Iniziato	Evercore ISI	In-line

Mostra tutto

Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie

01:26 AM

Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? - Finviz

01:26 AM

Feb 13, 2026

Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback? - simplywall.st

Feb 13, 2026

Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations (ALNY) - Seeking Alpha

Feb 13, 2026

RBC Capital lowers Alnylam Pharmaceuticals stock price target on short-term headwinds - Investing.com Canada

Feb 13, 2026

ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down - TradingView

Feb 13, 2026

Demystifying Alnylam Pharmaceuticals: Insights From 13 Analyst Reviews - Benzinga

Feb 13, 2026

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 13, 2026

RBC Lowers Price Target on Alnylam Pharmaceuticals to $450 From $465, Keeps Outperform Rating - marketscreener.com

Feb 13, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $425.00 at Chardan Capital - MarketBeat

Feb 13, 2026

Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback - Yahoo Finance

Feb 13, 2026

Is Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) ROE Of 19% Impressive? - Yahoo Finance

Feb 13, 2026

Rhumbline Advisers Sells 3,988 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Feb 13, 2026

Alnylam turns a profit for first time in 24-year history - The Business Journals

Feb 12, 2026

Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q4 2025 Earnings Conference - 富途牛牛

Feb 12, 2026